FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2543913731> ?p ?o ?g. }

• W2543913731 endingPage "A479" @default.
• W2543913731 startingPage "A478" @default.
• W2543913731 abstract "To examine the current EU5 market access landscape for ATMPs. Assessed the regulatory path, HTA assessments and funding mechanisms for ATMPs with EMA approval as of May 2016. Eight ATMPs are EMA approved as of May 2016. Of these, one was suspended (matrix-induced autologous chondrocyte implantation) and another withdrawn (sipuleucel-T). Germany: All ATMPs need to be authorised by the Paul Ehrlich Institute (PEI). Furthermore, the GBA could classify an ATMP as a procedure rather than a drug thereby bypassing AMNOG (e.g. autologous human corneal epithelial cells). The two ATMPs assessed under AMNOG (alipogene tiparvovec and sipuleucel-T), were both assigned “non-quantifiable additional benefit”. Talimogene laherparepvec is currently undergoing assessment with a final decision expected in mid-Dec 2016. Currently, alipogene tiparvovec is a hospital use only drug with reimbursement negotiated by the hospital and sickness funds on a case by case basis. In France, HAS assessed only two ATMPs (autologous cultured chondrocytes and alipogene tiparvovec) with reimbursement not being granted for either. Autologous cultured chondrocytes is the only ATMP that hospitals in Italy can currently import while it is available for hospital use only in Spain. Preliminary UK recommendation for autologous cultured chondrocytes and matrix-induced autologous chondrocyte implantation was for use in research only. Draft guidance on talimogene laherparepvec issued by NICE in March 2016 did not recommend use in melanoma. No other ATMP is currently routinely commissioned. All EMA approved ATMPs to date have faced EU5 market access challenges, with Germany being particularly complex. HTA assessments have been unfavourable largely due to the uncertainty with available data and – possibly – costs. The ATMP landscape is beginning to form and evolve. It will need to solidify for AMTPs to be viable for the companies seeking to market them and the patients who will benefit." @default.
• W2543913731 created "2016-11-04" @default.
• W2543913731 creator A5004203473 @default.
• W2543913731 creator A5022771745 @default.
• W2543913731 creator A5052293106 @default.
• W2543913731 creator A5066880394 @default.
• W2543913731 creator A5089776661 @default.
• W2543913731 date "2016-11-01" @default.
• W2543913731 modified "2023-09-30" @default.
• W2543913731 title "Advanced Therapy Medicinal Products (Atmps) In Europe 8 Years On: What Is The Path To Market Access So Far?" @default.
• W2543913731 doi "https://doi.org/10.1016/j.jval.2016.09.763" @default.
• W2543913731 hasPublicationYear "2016" @default.
• W2543913731 type Work @default.
• W2543913731 sameAs 2543913731 @default.
• W2543913731 citedByCount "1" @default.
• W2543913731 countsByYear W25439137312018 @default.
• W2543913731 crossrefType "journal-article" @default.
• W2543913731 hasAuthorship W2543913731A5004203473 @default.
• W2543913731 hasAuthorship W2543913731A5022771745 @default.
• W2543913731 hasAuthorship W2543913731A5052293106 @default.
• W2543913731 hasAuthorship W2543913731A5066880394 @default.
• W2543913731 hasAuthorship W2543913731A5089776661 @default.
• W2543913731 hasBestOaLocation W25439137311 @default.
• W2543913731 hasConcept C160735492 @default.
• W2543913731 hasConcept C17744445 @default.
• W2543913731 hasConcept C199539241 @default.
• W2543913731 hasConcept C2779703844 @default.
• W2543913731 hasConcept C2989108626 @default.
• W2543913731 hasConcept C71924100 @default.
• W2543913731 hasConcept C98274493 @default.
• W2543913731 hasConceptScore W2543913731C160735492 @default.
• W2543913731 hasConceptScore W2543913731C17744445 @default.
• W2543913731 hasConceptScore W2543913731C199539241 @default.
• W2543913731 hasConceptScore W2543913731C2779703844 @default.
• W2543913731 hasConceptScore W2543913731C2989108626 @default.
• W2543913731 hasConceptScore W2543913731C71924100 @default.
• W2543913731 hasConceptScore W2543913731C98274493 @default.
• W2543913731 hasIssue "7" @default.
• W2543913731 hasLocation W25439137311 @default.
• W2543913731 hasOpenAccess W2543913731 @default.
• W2543913731 hasPrimaryLocation W25439137311 @default.
• W2543913731 hasRelatedWork W1489783725 @default.
• W2543913731 hasRelatedWork W1506200166 @default.
• W2543913731 hasRelatedWork W2039318446 @default.
• W2543913731 hasRelatedWork W2048182022 @default.
• W2543913731 hasRelatedWork W2080531066 @default.
• W2543913731 hasRelatedWork W2604872355 @default.
• W2543913731 hasRelatedWork W2748952813 @default.
• W2543913731 hasRelatedWork W2899084033 @default.
• W2543913731 hasRelatedWork W3032375762 @default.
• W2543913731 hasRelatedWork W3108674512 @default.
• W2543913731 hasVolume "19" @default.
• W2543913731 isParatext "false" @default.
• W2543913731 isRetracted "false" @default.
• W2543913731 magId "2543913731" @default.
• W2543913731 workType "article" @default.